Evidence map›Paper›PMID 34018016›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2021

LMO3 reprograms visceral adipocyte metabolism during obesity.

Gabriel Wagner, Anna Fenzl, Josefine Lindroos-Christensen, Elisa Einwallner, Julia Husa, Nadine Witzeneder, Sabine Rauscher, Marion Gröger, Sophia Derdak, Thomas Mohr and 10 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. New Mediators in the Crosstalk between Different Adipose Tissues.International journal of molecular sciences · 2024
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 5 countries.

Gabriel Wagner *Department of Laboratory Medicine, Medical University of Vienna, 1090, Vienna, Austria.
Anna Fenzl *Clinical Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, 1090, Vienna, Austria.
Josefine Lindroos-ChristensenDepartment of Laboratory Medicine, Medical University of Vienna, 1090, Vienna, Austria.
Elisa EinwallnerDepartment of Laboratory Medicine, Medical University of Vienna, 1090, Vienna, Austria.
Julia HusaDepartment of Laboratory Medicine, Medical University of Vienna, 1090, Vienna, Austria.
Nadine WitzenederDepartment of Laboratory Medicine, Medical University of Vienna, 1090, Vienna, Austria.
Sabine RauscherCore Facilities, Medical University of Vienna, 1090, Vienna, Austria.
Marion GrögerCore Facilities, Medical University of Vienna, 1090, Vienna, Austria.
Sophia DerdakCore Facilities, Medical University of Vienna, 1090, Vienna, Austria.
Thomas MohrInstitute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, 1090, Vienna, Austria.
Hedwig SutterlütyInstitute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, 1090, Vienna, Austria.
Florian KlinglmüllerCenter for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, 1090, Vienna, Austria.
Silviya WolkerstorferDepartment of Laboratory Medicine, Medical University of Vienna, 1090, Vienna, Austria.
Martina FondiUniversity of Applied Sciences, FH Campus Wien, 1100, Vienna, Austria.
Gregor HoermannDepartment of Laboratory Medicine, Medical University of Vienna, 1090, Vienna, Austria.
Lei CaoDepartment of Cancer Biology and Genetics, The Ohio State University, Columbus, OH, 43210, USA.
Oswald WagnerDepartment of Laboratory Medicine, Medical University of Vienna, 1090, Vienna, Austria.
Florian W KieferClinical Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, 1090, Vienna, Austria.
Harald EsterbauerDepartment of Laboratory Medicine, Medical University of Vienna, 1090, Vienna, Austria.
Martin BilbanDepartment of Laboratory Medicine, Medical University of Vienna, 1090, Vienna, Austria. martin.bilban@meduniwien.ac.at.ORCID 0000-0001-7043-7142
Medical University of Vienna · ATComprehensive Cancer Center Vienna · ATHochschule Campus Wien · ATNovo Nordisk (Denmark) · DKThe Ohio State University · USUniversity Hospital Innsbruck · AT

Funding

Cancer Prevention and Treatment by Activation of a Brain-Adipocyte AxisR01CA166590 · NCI · OHIO STATE UNIVERSITY · PI CAO, LEI · 2013 to 2022
$3.4M
The role of hypothalamic-sympathoneural-adipocyte axis in healthy agingR01AG041250 · NIA · OHIO STATE UNIVERSITY · PI CAO, LEI · 2013 to 2017
$1.6M
Identifying brain mediators distinguishing eustress and distress impact on cancerR01CA163640 · NCI · OHIO STATE UNIVERSITY · PI CAO, LEI · 2013 to 2017
$1.2M
The role of hypothalamic-sympathoneural-adipocyte axis in healthy agingR56AG041250 · NIA · OHIO STATE UNIVERSITY · PI CAO, LEI · 2019 to 2019
$390k
Modulating cancer progression by adipogenic human adenovirus type 36R21CA178227 · NCI · OHIO STATE UNIVERSITY · PI CAO, LEI · 2013 to 2014
$375k
NCI NIH HHS R01 CA163640NCI NIH HHS R01 CA166590NCI NIH HHS R21 CA178227NIA NIH HHS R01 AG041250NIA NIH HHS R56 AG041250
6 · The paper itself

Abstract

Obesity and body fat distribution are important risk factors for the development of type 2 diabetes and metabolic syndrome. Evidence has accumulated that this risk is related to intrinsic differences in behavior of adipocytes in different fat depots. We recently identified LIM domain only 3 (LMO3) in human mature visceral adipocytes; however, its function in these cells is currently unknown. The aim of this study was to determine the potential involvement of LMO3-dependent pathways in the modulation of key functions of mature adipocytes during obesity. Based on a recently engineered hybrid rAAV serotype Rec2 shown to efficiently transduce both brown adipose tissue (BAT) and white adipose tissue (WAT), we delivered YFP or Lmo3 to epididymal WAT (eWAT) of C57Bl6/J mice on a high-fat diet (HFD). The effects of eWAT transduction on metabolic parameters were evaluated 10 weeks later. To further define the role of LMO3 in insulin-stimulated glucose uptake, insulin signaling, adipocyte bioenergetics, as well as endocrine function, experiments were conducted in 3T3-L1 adipocytes and newly differentiated human primary mature adipocytes, engineered for transient gain or loss of LMO3 expression, respectively. AAV transduction of eWAT results in strong and stable Lmo3 expression specifically in the adipocyte fraction over a course of 10 weeks with HFD feeding. LMO3 expression in eWAT significantly improved insulin sensitivity and healthy visceral adipose tissue expansion in diet-induced obesity, paralleled by increased serum adiponectin. In vitro, LMO3 expression in 3T3-L1 adipocytes increased PPARγ transcriptional activity, insulin-stimulated GLUT4 translocation and glucose uptake, as well as mitochondrial oxidative capacity in addition to fatty acid oxidation. Mechanistically, LMO3 induced the PPARγ coregulator Ncoa1, which was required for LMO3 to enhance glucose uptake and mitochondrial oxidative gene expression. In human mature adipocytes, LMO3 overexpression promoted, while silencing of LMO3 suppressed mitochondrial oxidative capacity. LMO3 expression in visceral adipose tissue regulates multiple genes that preserve adipose tissue functionality during obesity, such as glucose metabolism, insulin sensitivity, mitochondrial function, and adiponectin secretion. Together with increased PPARγ activity and Ncoa1 expression, these gene expression changes promote insulin-induced GLUT4 translocation, glucose uptake in addition to increased mitochondrial oxidative capacity, limiting HFD-induced adipose dysfunction. These data add LMO3 as a novel regulator improving visceral adipose tissue function during obesity. KEY MESSAGES: LMO3 increases beneficial visceral adipose tissue expansion and insulin sensitivity in vivo. LMO3 increases glucose uptake and oxidative mitochondrial activity in adipocytes. LMO3 increases nuclear coactivator 1 (Ncoa1). LMO3-enhanced glucose uptake and mitochondrial gene expression requires Ncoa1.

Indexed as

Energy Metabolism3T3-L1 CellsAdaptor Proteins, Signal TransducingAdipocytesAnimalsBiomarkersDisease Models, AnimalDisease SusceptibilityGene ExpressionGene Expression ProfilingGene Expression RegulationGlucoseGlucose Transporter Type 4HumansInsulinIntra-Abdominal FatAdaptor Proteins, Signal TransducingBiomarkersGlucoseGlucose Transporter Type 4InsulinLIM Domain ProteinsLMO3 protein, humanPPAR gammaLMO3ObesityVisceral adipose tissue

Identifiers

PMID34018016
PMCPMC8313462
OpenAlexW3161946320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.